{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-037053","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.515660+00:00","generated_at":"2026-05-29T04:59:55.038838+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"CervoMed Phase 2b DLB trial fails primary and secondary endpoints; neflamapimod no better than placebo","bullets":["Neflamapimod did not demonstrate statistically significant effects vs placebo on CDR-SB, TUG, NTD, or CGIC at 16 weeks.","Target plasma drug concentrations were not achieved during double-blind phase, likely negatively impacting results.","Favorable safety/tolerability profile with no new safety signal identified.","Company pausing all Phase 3 preparations for early-stage DLB until full analysis complete.","Full double-blind data expected January 2025; open-label first 16 weeks data expected late Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-037053","json":"https://secwatch.observer/filing/0001437749-24-037053.json","markdown":"https://secwatch.observer/filing/0001437749-24-037053.md","text":"https://secwatch.observer/filing/0001437749-24-037053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924037053/0001437749-24-037053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924037053/crvo20241209_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:59:55.038838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}